A national surveillance study of the current status of reirradiation using brachytherapy in Japan

Brachytherapy. 2021 Jan-Feb;20(1):226-231. doi: 10.1016/j.brachy.2020.07.007. Epub 2020 Sep 2.

Abstract

Purpose: This study aimed to explore the current status and pattern of practice for reirradiation using brachytherapy (ReRT-BT) through a survey in Japan.

Materials and methods: We distributed an e-mail-based questionnaire to 153 institutions equipped with high-dose-rate brachytherapy facilities.

Results: We received responses from 76 institutions (49.7%). Forty-three of these institutions performed ReRT-BT and 42 institutions (55%) performed ReRT-BT during 2009-2018. However, 29 of the 42 institutions (69%) reported difficulty in obtaining ReRT-BT case information from their respective databases. Almost all the institutions encountered insufficient database system to extract details about the ReRT-BT cases. Responses from 33 institutions included the number of ReRT-BT cases; this increased from 90 in the period 2009-2013 (institution median = 0.5; 0-16) to 172 in the period 2014-2018 (institution median = 2; 0-26). Nine institutions had to perform ReRT-BT for more than one case per year. The major location for cancer treatment was the pelvis (94%), followed by the head and neck (5%) and others (1%). In six site-specific scenarios, barring uterine corpus cancer recurrence, more than 90% of radiation oncologists agreed to perform ReRT-BT, whereas other areas (head and neck, prostate, and rectal cancer) gained 16-37% agreement.

Conclusions: This decade saw an increase in the number of ReRT-BT cases in Japan and radiation oncologists' interest in ReRT-BT as a viable therapeutic option. However, scarce availability, immature education system, and insufficient database system are barriers to further consensus building.

Keywords: Brachytherapy; HDR; LDR; Questionnaire survey; Reirradiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brachytherapy* / methods
  • Humans
  • Japan
  • Male
  • Neoplasm Recurrence, Local / radiotherapy
  • Prostatic Neoplasms*
  • Radiotherapy Dosage
  • Re-Irradiation*